PT  - JOURNAL ARTICLE
AU  - Hoyle, Brian
ED  - Tran, Tram
TI  - SOF Plus GS-5816 Effective in Noncirrhotic, Treatment-Naïve Patients Infected with HCV Genotypes 1 to 6
DP  - 2014  01
TA  - MD Conference Express
PG  - 17--17
VI  - 14
IP  - 48
4099  - http://mdc.sagepub.com/content/14/48/17.1.short
4100  - http://mdc.sagepub.com/content/14/48/17.1.full
AB  - The prowess of the nucleotide polymerase inhibitor sofosbuvir (SOF) against hepatitis C virus (HCV) is known. This article presents results from a study investigating a 12-week fixed-dose combination of SOF and nonstructural protein 5A (NS5A) inhibitor GS-5816 regimen in noncirrhotic, treatment-naïve HCV genotype 1 patients.